Last reviewed · How we verify
Iron Sucrose (Venofer)
Iron sucrose delivers iron directly into the bloodstream as a stable complex to replenish iron stores and treat iron deficiency anemia.
Iron sucrose delivers iron directly into the bloodstream as a stable complex to replenish iron stores and treat iron deficiency anemia. Used for Iron deficiency anemia in patients with chronic kidney disease on hemodialysis, Iron deficiency anemia in patients with chronic kidney disease not on dialysis, Iron deficiency anemia in patients receiving erythropoiesis-stimulating agents.
At a glance
| Generic name | Iron Sucrose (Venofer) |
|---|---|
| Also known as | Venofer |
| Sponsor | American Regent, Inc. |
| Drug class | Intravenous iron replacement agent |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Iron sucrose is an intravenous iron replacement therapy that provides bioavailable iron in a sucrose-stabilized form. The iron is absorbed and incorporated into hemoglobin and iron storage proteins (ferritin) to correct iron deficiency. This formulation is designed for patients who cannot tolerate or absorb oral iron, particularly those with chronic kidney disease on hemodialysis.
Approved indications
- Iron deficiency anemia in patients with chronic kidney disease on hemodialysis
- Iron deficiency anemia in patients with chronic kidney disease not on dialysis
- Iron deficiency anemia in patients receiving erythropoiesis-stimulating agents
Common side effects
- Hypotension
- Headache
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Injection site reactions
- Hypersensitivity reactions
Key clinical trials
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Comparison of the Mean Change in Hemoglobin With Ferric Carboxymaltose and IV Iron Sucrose in Anemic Antenatal Patients (NA)
- Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients (NA)
- Pilot Study Evaluating the Advantages of Sucrosomial® Iron Post-operative Supplementation vs Standard of Care After Cardiac Surgery (EARLY_PHASE1)
- Pharmacokinetic of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin (PHASE2)
- Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy (PHASE3)
- Perioperative Blood Conservation: Role of Combined Iron Supplementation Protocols in Reducing Allogeneic Transfusion (NA)
- Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iron Sucrose (Venofer) CI brief — competitive landscape report
- Iron Sucrose (Venofer) updates RSS · CI watch RSS
- American Regent, Inc. portfolio CI